Alkermes ALKS
NASDAQ ALKS
$45.36 -0.13 (-0.29%)
As of: Sep 9, 2026 · 3:43 PM EDT

Alkermes (ALKS) Interest & Investment Income (2010 - 2026)

Alkermes' (ALKS) quarterly Interest & Investment Income came in at $5.3 million in Q2 2026, down 51.81% year-over-year from $11.1 million in Q2 2025, and up 1040.85% quarter-over-quarter from -$568000.0 in Q1 2026.

Analysis

Alkermes (ALKS) Interest & Investment Income (2010 - 2026) Analysis & Trends

Alkermes (ALKS) has reported Interest & Investment Income for 17 consecutive years, with $5.3 million the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Interest & Investment Income fell 51.81% year-over-year to $5.3 million in Q2 2026; TTM through Jun 2026 was $28.8 million, a 14.94% decrease from a year earlier, with the FY2025 full-year figure at $45.3 million, up 6.72% from the prior year.
  • Interest & Investment Income was $5.3 million for Q2 2026 at Alkermes, up from -$568000.0 in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $16.7 million in Q4 2022 and troughed at -$4.5 million in Q1 2022.
  • A 5-year average of $5.1 million and a median of $4.1 million in 2023 frame the typical range for Interest & Investment Income.
  • Across the five-year window, Interest & Investment Income tumbled 728.68% in 2022 and soared 100718.18% in 2025, its largest moves.
  • Over 5 years, Interest & Investment Income stood at $16.7 million in 2022, then slumped by 41.77% to $9.7 million in 2023, then climbed by 16.94% to $11.4 million in 2024, then gained by 6.4% to $12.1 million in 2025, then tumbled by 55.94% to $5.3 million in 2026.
  • The last three Interest & Investment Income figures came in at $5.3 million (Q2 2026), -$568000.0 (Q1 2026), and $12.1 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Int & Inv Inc (Qtr)
1 Johnson & Johnson 645.38 Bn 624.62 Bn 17.26 Bn 219.00 Mn
2 AbbVie 443.49 Bn 436.92 Bn 12.70 Bn -679.00 Mn
3 Merck 365.35 Bn 358.21 Bn 12.21 Bn -
4 Novartis Ag 266.75 Bn 259.06 Bn 11.24 Bn -
5 Pfizer 158.55 Bn 146.85 Bn 10.94 Bn -
6 Sanofi 52.39 Bn 45.01 Bn 10.79 Bn 89.50 Mn
7 Revolution Medicines 43.97 Bn 43.97 Bn - 35.58 Mn
8 Incyte 25.35 Bn 20.82 Bn 1.57 Bn 38.12 Mn
9 United Therapeutics 21.57 Bn 18.91 Bn 683.80 Mn 31.50 Mn
10 Alkermes 7.57 Bn 6.92 Bn 397.90 Mn 5.34 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 5.34 Mn
Mar 31, 2026 -568,000.00
Dec 31, 2025 12.13 Mn
Sep 30, 2025 11.94 Mn
Jun 30, 2025 11.09 Mn
Mar 31, 2025 512,000.00
Dec 31, 2024 11.40 Mn
Sep 30, 2024 10.92 Mn
Jun 30, 2024 11,000.00
Mar 31, 2024 -491,000.00
Dec 31, 2023 9.75 Mn
Sep 30, 2023 9.37 Mn
Jun 30, 2023 692,000.00
Mar 31, 2023 2.76 Mn
Dec 31, 2022 16.74 Mn
Sep 30, 2022 -2.35 Mn
Jun 30, 2022 -2.25 Mn
Mar 31, 2022 -4.51 Mn
Dec 31, 2021 453,000.00
Sep 30, 2021 468,000.00